Final Trades: Berkshire, Devon Energy & CRISPR Therapeutics
In the latest edition of CNBC’s “Halftime Report,” the traders shared their top picks to watch for the second half of the trading day.
These picks include Berkshire Hathaway, Devon Energy, and CRISPR Therapeutics.
The traders provided insights based on technical analysis and recent developments in these companies.
Starting with CRISPR Therapeutics, the stock is currently priced at $62.40.
The traders highlighted the company’s potential, considering its advancements in the field of gene editing technology.
CRISPR Therapeutics has been making significant progress in developing innovative therapies that utilize CRISPR-Cas9 gene editing techniques.
Next on the list is Devon Energy, which recently reported a strong quarter.
The company impressed investors by announcing a 50% increase to their buyback operation.
This move indicates Devon Energy’s confidence in its future prospects and commitment to enhancing shareholder value.
Lastly, Berkshire Hathaway caught the attention of the traders, who expressed optimism about the company’s succession plan.
Following discussions over the weekend, the traders came away with a positive outlook on the future leadership of Berkshire Hathaway, particularly with Todd and [individual’s name].
These “Final Trades” reflect the traders’ assessments of the market and their belief in the potential of these companies.
Investors and market participants may consider keeping an eye on Berkshire Hathaway, Devon Energy, and CRISPR Therapeutics as they navigate the second half of the trading day.
Please note that this article is based on the information provided and does not reflect any TV channel, download information, or specific news title.
